The effect of dapagliflozin treatment on epicardial adipose tissue volume
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The effect of dapagliflozin treatment on epicardial adipose tissue volume
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 17, Issue 1, Pages -
Publisher
Springer Nature
Online
2018-01-04
DOI
10.1186/s12933-017-0658-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- Ipragliflozin Reduces Epicardial Fat Accumulation in Non-Obese Type 2 Diabetic Patients with Visceral Obesity: A Pilot Study
- (2017) Tatsuya Fukuda et al. Diabetes Therapy
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
- (2016) Christian Sonesson et al. Cardiovascular Diabetology
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Changes in Levels of Biomarkers Associated with Adipocyte Function and Insulin and Glucagon Kinetics During Treatment with Dapagliflozin Among Obese Type 2 Diabetes Mellitus Patients
- (2016) Aki Okamoto et al. Drugs in research & development
- The Selective SGLT2 Inhibitor Ipragliflozin Has a Therapeutic Effect on Nonalcoholic Steatohepatitis in Mice
- (2016) Yasushi Honda et al. PLoS One
- Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction
- (2016) Chikara Komiya et al. PLoS One
- SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials
- (2015) Silvio E Inzucchi et al. Diabetes & Vascular Disease Research
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta-analysis
- (2015) S. W. Rabkin et al. Obesity Reviews
- Increased Epicardial Adipose Tissue Thickness in Type 2 Diabetes Mellitus and Obesity
- (2015) Do Kyeong Song et al. Diabetes & Metabolism Journal
- A reduction in both visceral and subcutaneous fats contributes to increased adiponectin by lifestyle intervention in the Diabetes Prevention Program
- (2014) Chao Zhang et al. ACTA DIABETOLOGICA
- Effects of Eicosapentaenoic Acid Treatment on Epicardial and Abdominal Visceral Adipose Tissue Volumes in Patients with Coronary Artery Disease
- (2014) Takao Sato et al. Journal of Atherosclerosis and Thrombosis
- Epicardial Adipose Tissue Volume and Adipocytokine Imbalance Are Strongly Linked to Human Coronary Atherosclerosis
- (2013) Michio Shimabukuro et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Association of Epicardial Fat With Cardiovascular Risk Factors and Incident Myocardial Infarction in the General Population
- (2013) Amir A. Mahabadi et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
- (2013) William T Cefalu et al. LANCET
- Insulin Resistance: Metabolic Mechanisms and Consequences in the Heart
- (2012) E. Dale Abel et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Adipose tissue heterogeneity: Implication of depot differences in adipose tissue for obesity complications
- (2012) Mi-Jeong Lee et al. MOLECULAR ASPECTS OF MEDICINE
- Inflammatory Genes in Epicardial Fat Contiguous With Coronary Atherosclerosis in the Metabolic Syndrome and Type 2 Diabetes: Changes associated with pioglitazone
- (2011) H. S. Sacks et al. DIABETES CARE
- Enhanced Inflammation in Epicardial Fat in Patients With Coronary Artery Disease
- (2011) Yoichiro Hirata et al. International Heart Journal
- Coronary Atherosclerosis Is Associated With Macrophage Polarization in Epicardial Adipose Tissue
- (2011) Yoichiro Hirata et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Weight of Pericardial Fat on Coronaropathy
- (2009) Karine Clément et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study
- (2009) Adam G Tabák et al. LANCET
- Substantial Changes in Epicardial Fat Thickness After Weight Loss in Severely Obese Subjects
- (2008) Gianluca Iacobellis et al. Obesity
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now